

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

**POLL RESULTS OF THE RESOLUTIONS PROPOSED AT
THE 2023 FIRST EXTRAORDINARY GENERAL MEETING
HELD ON MONDAY, 28 AUGUST 2023**

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Henlius Biotech, Inc. (the “**Company**”) is pleased to announce the poll results of the 2023 first extraordinary general meeting (the “**EGM**”) held at Conference Room, 5th Floor, Innov Tower (Capitaland Building), Section A, 1801 Hongmei Road, Shanghai, PRC at 3:30 p.m. on Monday, 28 August 2023.

References are made to the notice and the circular (the “**Circular**”) of the Company both dated 11 August 2023 in relation to the EGM. Unless the context otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

EGM

As at the date of the EGM, the total number of the issued shares of the Company (the “**Shares**”) was 543,494,853 Shares, comprising 364,189,618 domestic Shares, 15,876,694 unlisted foreign Shares and 163,428,541 H Shares, all of which entitled the holders (or authorised representatives) to attend and vote on the resolutions proposed at the EGM (the “**Resolutions**”). Shareholders or authorised representatives holding an aggregate of 418,067,748 Shares with voting rights, representing approximately 76.922117% of the total number of the Shares with voting rights of the Company were present at the EGM. All Directors attended the EGM.

As disclosed in the Circular, Fosun Pharmaceutical Industrial, Fosun New Medicine and Fosun Industrial were required to abstain from voting on Resolution 3 at the EGM. As at the date of the EGM, Fosun Pharmaceutical Industrial, Fosun New Medicine and Fosun Industrial, which were interested in an aggregate of 323,696,487 Shares, representing approximately 59.558335% of the total issued shares of the Company, have abstained from voting on such Resolution.

Save as disclosed above, to the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, no Shareholder was required to abstain from voting on any of the Resolutions under the Listing Rules. There was no Share entitling the holder to attend the EGM and abstain from voting in favour of any of the Resolutions under Rule 13.40 of the Listing Rules. No Shareholder has stated the intention in the Circular to vote against or to abstain from voting on any of the Resolutions.

Pursuant to Listing Rules and the articles of association of the Company (the “**Articles of Association**”), Computershare Hong Kong Investor Services Limited, representatives from the Shareholders and a member of the board of supervisors of the Company acted as the scrutineers for vote-tabulation at the EGM.

The EGM was convened in compliance with the requirements of the Company Law of PRC and the Articles of Association. Mr. Wenjie Zhang, chairman of the Board of the Company, acted as the chairman of the EGM.

POLL RESULTS OF THE EGM

The poll results in respect of the EGM Resolutions are as follows:

Ordinary Resolutions		Number of valid votes and percentage of total number of votes (%)		
		For	Against	Abstain
1.	To consider and approve the resolution in relation to the appointment of Mr. Jun Zhu as an executive director of the Company.	418,042,160 (99.993879%)	25,585 (0.006120%)	3 (0.000001%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				
2.	To consider and approve the resolution in relation to the appointment of Dr. XINGLI WANG as a non-executive director of the Company.	418,010,911 (99.986405%)	56,834 (0.013594%)	3 (0.000001%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				
3.	To consider and, if thought fit, approve the amendment to license and supply agreement dated 9 August 2023 entered into between the Company and Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司) (the “ Amendment to License Agreement ”) as set out in the circular of the Company dated 11 August 2023 (including the transactions contemplated thereunder); and to authorise any Director to exercise all powers which they consider necessary and do such other acts and things and execute such other documents which in their opinion may be necessary or desirable to implement the transactions contemplated under the Amendment to License Agreement.	94,370,261 (99.998940%)	1,000 (0.001060%)	0 (0.000000%)
As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.				

Special Resolution		Number of valid votes and percentage of total number of votes (%)		
		For	Against	Abstain
4.	To consider and approve the resolution in relation to the proposed amendments to the Articles of Association and Rules of Procedures for the Board, which will take effect immediately upon approval at the EGM.	418,066,748 (99.999761%)	1,000 (0.000239%)	0 (0.000000%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.				

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie ZHANG
Chairman

Hong Kong, 28 August 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang and Mr. Jun Zhu as the executive directors, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.